febit holding gmbh launched the first human cancer biochip for HybSelect, febit’s automated technology for sequence capture, enabling targeted next-generation sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute.
The availability of the automated HybSelect technology supports large-cohort NGS studies that aim to elucidate complex diseases such as cancer, drive forward personalized medicine and investigate new therapeutic delivery models. febit will include key research study results in the next generation of its cancer biochips. A 2Mb exon cancer biochip will be available this summer and a 30Mb biochip is planned already for release in 2010.
Multiplex NGS studies based on sequence capture can be supplemented by other molecular fingerprinting methods, including mRNA and miRNA expression profiling. Both of these high-throughput methods can be performed using the same febit technology as HybSelect, thereby reducing capital expenditures and minimizing experimental variation. HybSelect and expression profiling can easily be performed in the researcher’s lab operating a Geniom RT Analyzer from febit or by using febit’s convenient analytical services.
Filed Under: Drug Discovery
